Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1109 / NExT study in resectable locally advanced thoracic esophageal squamous cell carcinoma
jRCTs031180202Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, fluorouracil and docetaxel in Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenosquamous carcinoma (ASC) and esophageal basaloid squamous cell carcinoma (BSCC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Dec 2012; status: completed.
02
Drugs
cisplatinfluorouracildocetaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)esophageal adenosquamous carcinoma (ASC)esophageal basaloid squamous cell carcinoma (BSCC)
Beyond the preview
Go deeper on jRCTs031180202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180202.